3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Triple Negative Breast Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Carcinoma
1
Breast Neoplasms, Male
1
Breast Neoplasms
1
Interventions
Paclitaxel
71
Bevacizumab
64
Carboplatin
56
pembrolizumab
46
olaparib
32
Gemcitabine
29
Specimen Handling
27
Cyclophosphamide
26
liposomal doxorubicin
24
Magnetic Resonance Spectroscopy
24
Cisplatin
22
niraparib
21
Taxes
19
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
13
Disulfides
13
Fulvestrant
12
Blood Specimen Collection
11
durvalumab
10
Oxaliplatin
10
mirvetuximab soravtansine
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Indomethacin
×
1 year
×
Clear all
NCT01719926
2026-06-04
PIFA
UMC Utrecht
Phase 1
Completed
13 enrolled